These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24883155)

  • 21. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
    Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
    Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
    Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
    Wu W; Li Y; Chen X; Lin D; Xiang S; Shen F; Gu X
    Med Sci Monit; 2015 Sep; 21():2678-84. PubMed ID: 26350766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid.
    Kutoh E; Kuto AN; Akiyama M; Ozawa E; Kurihara R
    Eur J Clin Pharmacol; 2023 Jul; 79(7):947-959. PubMed ID: 37193913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
    Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of Adipose Tissue Insulin Resistance and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
    Kutoh E; Kuto AN; Ozawa E; Kurihara R; Akiyama M
    Drug Res (Stuttg); 2023 Jun; 73(5):279-288. PubMed ID: 36882112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Pioglitazone on Serum Uric Acid Levels in Newly Diagnosed, Drug-Naïve Patients with Type 2 Diabetes.
    Kutoh E; Hori T
    Endocr Res; 2013 Aug; 38(3):151-159. PubMed ID: 23216460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study.
    Agarwal P; Jindal C; Sapakal V
    Indian J Endocrinol Metab; 2018; 22(1):41-46. PubMed ID: 29535935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Teneligliptin on HbA1c levels, Continuous Glucose Monitoring-Derived Time in Range and Glycemic Variability in Elderly Patients with T2DM (TEDDY Study).
    Bae JC; Kwak SH; Kim HJ; Kim SY; Hwang YC; Suh S; Hyun BJ; Cha JE; Won JC; Kim JH
    Diabetes Metab J; 2022 Jan; 46(1):81-92. PubMed ID: 34130378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diverse Strategies for Modulating Insulin Resistance: Causal or Consequential Inference on Metabolic Parameters in Treatment-Naïve Subjects with Type 2 Diabetes.
    Kutoh E; Kuto AN; Okada R; Akiyama M; Kurihara R
    Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929608
    [No Abstract]   [Full Text] [Related]  

  • 32. Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties.
    Kutoh E; Kaneoka N; Hirate M
    Endocr Res; 2015; 40(2):88-96. PubMed ID: 25208188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin.
    Kutoh E; Hirate M; Wada A
    Int J Clin Pract; 2015 Nov; 69(11):1296-302. PubMed ID: 26194442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.
    Han E; Lee M; Lee YH; Kim HS; Lee BW; Cha BS; Kang ES
    Diabetes Metab Syndr Obes; 2020; 13():4113-4121. PubMed ID: 33173319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
    Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
    Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
    Kim MK; Rhee EJ; Han KA; Woo AC; Lee MK; Ku BJ; Chung CH; Kim KA; Lee HW; Park IB; Park JY; Chul Jang HC; Park KS; Jang WI; Cha BY
    Diabetes Obes Metab; 2015 Mar; 17(3):309-12. PubMed ID: 25475929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
    Aso Y; Kase M; Sagara M; Sakurai S; Iijima T; Tomaru T; Jojima T; Usui I
    Am J Med Sci; 2020 Sep; 360(3):261-267. PubMed ID: 32540146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
    Kamiko K; Aoki K; Kamiyama H; Taguri M; Shibata E; Ashiya Y; Minagawa F; Shinoda K; Nakajima S; Terauchi Y
    J Clin Pharmacol; 2015 Feb; 55(2):144-51. PubMed ID: 25159300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.